Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system

Clinical Drug Investigation

Volumn 32, Issue 9, 2012, Pages 583-592

  Kapil, Ram P ^a   Cipriano, Alessandra ^a   Michels, Gregory H ^a   Perrino, Peter ^a   Okeefe, Sarah A ^a   Shet, Manjunath S ^a   Colucci, Salvatore V ^a   Noveck, Robert J ^b   Harris, Stephen C ^a  

^a PURDUE PHARMA L P   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

buprenorphine; ketoconazole; pharmacokinetics

Indexed keywords

BUPRENORPHINE; CREATININE; CYTOCHROME P450 3A4; DRUG METABOLITE; KETOCONAZOLE; NORBUPRENORPHINE; NORBUPRENORPHINE 3BETA GLUCURONIDE; PLACEBO; UNCLASSIFIED DRUG;

ACNE; ADULT; APPLICATION SITE PRURITUS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHEMA; FEMALE; FLUSHING; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AREA UNDER CURVE; BREATH TESTS; BUPRENORPHINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; KETOCONAZOLE; MIDDLE AGED; PLACEBOS; YOUNG ADULT;

EID: 84865121146     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11633060-000000000-00000     Document Type: Article

References (32)

1. BUTRANS-(transdermal buprenorphine) [package insert]. Stamford (CT): Purdue Pharma L.P., 2011 Jun
2. Ohtani M. Basic pharmacology of buprenorphine. Eur J Pain Suppl. 2007; 1 (1): 69-73 (Pubitemid 351597815)
3. Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001; 297 (2): 688-95 (Pubitemid 32378001)
4. Zhou S-F, Xue CC, Yu X-Q, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007 Dec; 29: 687-710 (Pubitemid 350190847)
5. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005 Sep; 28 (9): 1805-8 (Pubitemid 41324160)
6. Grü n B, Krautter S, Riedel K-D, et al. Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole. Br J Clin Pharmacol 2009; 68 (5): 712-20
7. SUBOXONE-(buprenorphine HCl and naloxone HCl dihydrate sublingual tablets); SUBUTEX-(buprenophine HCl sublingual tablets) [package insert]. Richmond (VA): Reckitt Benckiser Pharmaceuticals, Inc., 2006 Sep
8. Oo C, Chen Y-C. The need for multiple doses of 400mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study [letter]. J Clin Pharmacol 2009; 49: 368-9
9. Siegsmund MJ, Cardarelli C, Aksentijevich I, et al. Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 1994 Feb; 151 (2): 485-91 (Pubitemid 24047040)
10. Reidenberg B, El-Tahtawy A, Munera C, et al. Absolute bioavailability of a novel buprenorphine transdermal system (BTDS) applied for 7 days. J Clin Pharmacol 2001 Sep; 41 (9): 1026, abstract 55
11. Huang S-M, Temple R, Throckmorton DC, et al. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007 Feb; 81: 298-304 (Pubitemid 46174829)
12. Zhao P, Ragueneau-Majlessi I, Zhang L, et al. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 2009 Mar; 49: 351-9
13. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharmaceut 2004 Jun 11; 277: 3-9 (Pubitemid 38670415)
14. Matsson E. In vivo pharmacokinetics of two new thrombin inhibitor prodrugs: emphasis on intestinal and hepatobiliary disposition and the influence of interacting drugs [dissertation]. Uppsala: Acta Universitatis Upsaliensis, 2010
15. Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg 2009 Jun; 28: 77-85
16. Woolery-Lloyd H, Kammer JN. Treatment of hyperpigmentation. Semin Cutan Med Surg 2011 Sep; 30: 171-5
17. Ale I, Lachapelle J-M, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther 2009 Oct; 26 (10): 920-35
18. Bullingham RES, McQuay HJ, Porter EJB, et al. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol 1982 May; 13: 665-73 (Pubitemid 13139882)
19. McQuay HJ, Moore RA. Buprenorphine kinetics in humans. In: Cowan A, Lewis JW, editors. Buprenorphine: combatting drug abuse with a unique opioid. New York (NY): Wiley-Liss, Inc., 1995: 137-47
20. Mendelson J, Upton RA, Everhart T, et al. Bioavailability of sublingual buprenorphine. JClin Pharmacol 1997 Jan; 37: 31-7 (Pubitemid 27131552)
21. Kuhlman JJ, Lalani S, Magluilo J, et al. Human pharmacokinetics of intravenous, sublingual and buccal buprenorphine. J Anal Toxicol 1996 Oct; 20: 369-78 (Pubitemid 26327458)
22. Jones RT, Mendelson J, Upton R. An open-label, partially blinded, balanced 4 · 4 latin square crossover study to evaluate the pharmacokinetic and dose-proportionality of buprenorphine when administered in sublingual tablets alone or in combination with naloxone in independent opiate users. NIDA Contract N01DA-4-8306 report, pharmacokinetic and pharmacodynamic studies for medication development. 1997
23. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007 Dec 1; 91: 269-78 (Pubitemid 47539730)
24. Wilkinson GR, Shand DG. Commentary: a physiologic approach to hepatic drug clearance. Clin Pharmacol Ther 1975 Oct; 18 (4): 377-90
25. Lundahl J, Regardh CG, Edgar B, et al. Effects of grapefruit juice ingestion: pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997; 52: 139-45 (Pubitemid 27239599)
26. Ogilvie BW, Usuki E, Yerino P, et al. In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying drug-metabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450. In Rodrigues AD, editor. Drug-drug interactions. 2nd ed. New York (NY): Informa Healthcare, 2008: 231-358
27. Ogasawara A, Masahiro U, Nii K, et al. Effect of oral ketoconazole on oral and intravenous pharmacokinetics of simvastatin and its acid in cynomolgus monkeys. Drug Metab Dispos 2009 Jan; 37: 122-8
28. Canafax DM, Graves NM, Hilligoss DM, et al. Increased cyclosporine levels as a result of simultaneous fluconazole and cyclosporine therapy in renal transplant recipients: a double-blind, randomized pharmacokinetic and safety study. Transplant Proc 1991 Feb; 23 (1 Pt 2): 1041-2
29. Canafax DM, Graves NM, Hilligoss DM, et al. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991 May; 51 (5): 1014-8
30. Osowski CL, Dix SP, Lin LS, et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996 Apr 27; 61: 1268-72 (Pubitemid 26134782)
31. Tsunoda SM, Velez RL, von Moltke LL, et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999 Nov; 66: 461-71
32. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism. Clin Pharmacokinet 2000 Feb; 38: 111-80 (Pubitemid 30122116)